Enclomiphene For Fertility-Friendly Testosterone Support

Enclomiphene is a selective estrogen receptor modulator (SERM) studied as a path to fertility-friendly testosterone for men who want to protect fertility. It is not testosterone. Rather than adding the hormone from outside, enclomiphene prompts the testes to make more of their own, of interest to men with low testosterone who hope to conceive.

That goal shapes how a lab-based telehealth provider approaches care. Conventional testosterone replacement therapy (TRT) raises testosterone but tends to suppress sperm production (Bhasin, 2018).

Enclomiphene citrate is the trans-isomer of clomiphene. As a SERM, it blocks estrogen's feedback at the hypothalamus and pituitary, raising luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and signaling the testes to produce more testosterone. Because it raises the body's own testosterone, enclomiphene can support spermatogenesis in men with secondary hypogonadism.

How enclomiphene supports fertility-friendly testosterone

Enclomiphene supports fertility-friendly testosterone by acting upstream, at the brain's hormone controls. Sperm production depends on a feedback loop: the hypothalamus releases gonadotropin-releasing hormone (GnRH), prompting the pituitary to release LH and FSH. LH drives the testes' Leydig cells to make testosterone, and FSH supports the Sertoli cells that mature sperm.

Exogenous testosterone, used in testosterone replacement therapy, dampens that loop. When the body senses testosterone from outside, its own LH and FSH fall and sperm production tends to drop, which is why the Endocrine Society advises against testosterone for men who want to conceive soon (Bhasin, 2018). Enclomiphene works the other way, blocking estrogen feedback so the testes keep producing testosterone and sperm.

Based on short-term trial data; individual responses vary.

Can enclomiphene maintain sperm production?

Limited evidence suggests enclomiphene may help maintain sperm production while raising testosterone. In two randomized phase III trials in overweight men with secondary hypogonadism, enclomiphene raised testosterone and increased LH and FSH while preserving sperm counts, whereas a testosterone gel raised testosterone but lowered them (Kim, 2016). These short trials tracked sperm counts, not pregnancy, so effects on fertility itself are uncertain.

A 2025 meta-analysis found similar results. SERMs such as clomiphene and enclomiphene raised testosterone, LH, and FSH in men with functional hypogonadism while preserving spermatogenesis (Hohl, 2025). Men already on testosterone should raise maintaining fertility on TRT with a provider early.

How does enclomiphene compare to clomiphene (Clomid)?

Enclomiphene is generally considered the more active of the two isomers in clomiphene citrate (Clomid), and guidelines treat both as off-label options for fertility preservation rather than approved testosterone treatments (Mulhall, 2018). Clomid is FDA-approved only for female infertility but is sometimes prescribed off-label to men. Its other isomer is zuclomiphene.

The isomers behave differently. Enclomiphene, the trans-isomer, blocks estrogen receptors in the brain and raises testosterone. Zuclomiphene, the longer-acting isomer, acts more like estrogen and may contribute to effects such as breast tenderness or mood changes in some men. Long-term safety data for enclomiphene are limited, and like other SERMs it may cause mood or visual changes; men sensitive to estrogen shifts can track estradiol levels with their provider.

Neither enclomiphene nor off-label clomiphene is FDA-approved for male hypogonadism, and compounded enclomiphene is not an FDA-approved product. The Endocrine Society bases any diagnosis on symptoms of low testosterone plus low morning testosterone confirmed on repeat testing (Bhasin, 2018). Enclomiphene and clomiphene require a prescription after clinician evaluation; testosterone is a Schedule III controlled substance, and access depends on state law.

For some men with secondary hypogonadism, enclomiphene is a fertility-friendly testosterone option that raises the body's own production while helping preserve sperm. It is not right for everyone, and the trial evidence is still early. Conventional TRT carries its own monitoring needs; the TRAVERSE trial found no increase in major adverse cardiac events versus placebo, though atrial fibrillation and pulmonary embolism were more frequent with testosterone (Lincoff, 2023). Anyone weighing these options should base the decision on symptoms, repeat lab testing, and evaluation by a licensed clinician, with treatment prescribed only when medically appropriate.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Is enclomiphene a fertility-friendly testosterone option? 

Yes, in the sense that it raises a man's own testosterone while helping preserve sperm production, unlike conventional TRT. In randomized phase III trials, enclomiphene increased testosterone and kept sperm counts steady, whereas a testosterone gel lowered them. It is not FDA-approved, so a clinician decides whether it fits.

Is enclomiphene FDA-approved for low testosterone? 

No. Enclomiphene is not FDA-approved for hypogonadism or any indication. It may be available through compounding pharmacies for patients with a valid prescription, though its compounding status can change and availability is not guaranteed. Clomiphene (Clomid), which contains enclomiphene, is FDA-approved only for female infertility.

Does enclomiphene preserve fertility better than TRT? 

Trials suggest enclomiphene may help preserve sperm counts while raising testosterone, whereas testosterone gel raised testosterone but reduced sperm counts. These trials measured sperm counts rather than conception, so fertility outcomes are variable rather than guaranteed. A provider should guide the choice based on labs and goals.

How does enclomiphene differ from testosterone injections? 

Enclomiphene stimulates the body's own LH, FSH, and testosterone rather than supplying the hormone directly. Because it keeps the brain's signals to the testes active, it tends not to suppress sperm production the way exogenous testosterone does.

What monitoring does enclomiphene treatment involve? 

A clinician typically follows hormone levels and related labs over time. Diagnosis and follow-up rest on symptoms plus low morning testosterone confirmed on repeat testing. Monitoring is provider-directed and individualized rather than a fixed schedule.

Who is a candidate for enclomiphene as a fertility-friendly testosterone approach? 

Enclomiphene is studied mainly in men with secondary (hypogonadotropic) hypogonadism who want to preserve fertility. A diagnosis requires symptoms plus low morning testosterone confirmed on repeat testing, and a clinician decides whether it is appropriate.

References

• Arch Endocrinol Metab. 2025;69(5):e250093.

• BJU Int. 2016;117(4):677-685.

• J Clin Endocrinol Metab. 2018;103(5):1715-1744.

• J Urol. 2018;200(2):423-432.

• N Engl J Med. 2023;389:107-117.